AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 22 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Current World Health Organization recommendations for measles immunization in developing countries may be re-evaluated following the results of a study of the regimen in Turkish children.
Lingering maternal antibodies may compromise the standard practice of giving the monovalent measles vaccine (MV) at nine months, followed by the measles-mumps-rubella (MMR) vaccine at 15 months, suggested M. Ceyhan and colleagues, who compared 442 children receiving the MV/MMR regimen to 495 children who received a single dose of MMR at 12 months of age with no earlier vaccination.
Antibody measurements taken before the first vaccination and six months after the MMR vaccine indicated that seroconversion and clinical protection rates were significantly higher in children who received only MMR at 12 months compared with those who were revaccinated at 15 months, reported Ceyhan et al.
In addition, while 12 children from the double-vaccine group acquired measles during the 60-month follow-up period, none from the single-vaccine group was infected ("Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR ...
Source: HighBeam Research, Single MMR Vaccine At 12 Months More Protective Than Booster At 15...